Neutrophil Phenotypic Profiling and Acute Lung Injury in Patients After Cardiopulmonary Bypass (CPB)
Launched by SOPHIA KOUTSOGIANNAKI · Mar 3, 2020
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a procedure called cardiopulmonary bypass (CPB) can lead to a serious condition known as acute lung injury (ALI) in young children. After heart surgery that requires CPB, some children may experience problems with their lungs, which can keep them in the intensive care unit (ICU) longer and can even be life-threatening. The researchers want to understand how this happens in order to improve care and outcomes for these patients.
To participate in the trial, children must be under 12 months old and scheduled for heart surgery that requires CPB. They also need to have a certain level of oxygen in their blood before the surgery. Unfortunately, children who don't meet these conditions, such as those needing oxygen therapy or with low oxygen levels before surgery, cannot take part. If eligible, participants will undergo regular assessments to help the researchers learn more about how CPB affects lung health. This study is currently recruiting participants, and parents or guardians will need to give their consent for their child to join.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Are \< 12months of age
- • Scheduled for cardiac surgical needing CPB
- • Preoperative SpO2 \> 90%
- Exclusion Criteria:
- • Lack of parental (or legal guardian's) consent
- • Preoperative SpO2 \< 90%
- • Preoperative oxygen therapy
About Sophia Koutsogiannaki
Sophia Koutsogiannaki is a dedicated clinical trial sponsor committed to advancing medical research and enhancing patient care through innovative studies. With a focus on developing effective therapeutic solutions, her organization emphasizes rigorous scientific methodologies and ethical practices in clinical trials. Leveraging a multidisciplinary team of experts, Sophia Koutsogiannaki aims to facilitate the successful translation of promising research into tangible health outcomes, ensuring compliance with regulatory standards while prioritizing patient safety and well-being. Through collaborative partnerships and a patient-centered approach, she strives to contribute significantly to the advancement of healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials